BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18753823)

  • 1. Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET.
    Tsamita CS; Golemi A; Egesta L; Castellucci P; Nanni C; Stefoni V; Grassetto G; Rubello D; Tani M; Zinzani PL; Fanti S
    Nucl Med Commun; 2008 Aug; 29(8):705-10. PubMed ID: 18753823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma.
    Crocchiolo R; Fallanca F; Giovacchini G; Ferreri AJ; Assanelli A; Verona C; Pescarollo A; Bregni M; Ponzoni M; Gianolli L; Fazio F; Ciceri F
    Ann Hematol; 2009 Dec; 88(12):1229-36. PubMed ID: 19468730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
    Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S
    Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.
    García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
    Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
    Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma.
    Zinzani PL; Stefoni V; Tani M; Fanti S; Musuraca G; Castellucci P; Marchi E; Fina M; Ambrosini V; Pellegrini C; Alinari L; Derenzini E; Montini G; Broccoli A; Bacci F; Pileri S; Baccarani M
    J Clin Oncol; 2009 Apr; 27(11):1781-7. PubMed ID: 19273712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET in children with lymphomas.
    Depas G; De Barsy C; Jerusalem G; Hoyoux C; Dresse MF; Fassotte MF; Paquet N; Foidart J; Rigo P; Hustinx R
    Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):31-8. PubMed ID: 15605288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
    Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
    Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of FDG positron emission tomography imaging on the management of lymphomas.
    Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
    Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
    Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
    Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
    Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
    Juweid ME
    J Nucl Med; 2008 Jan; 49(1):9-12. PubMed ID: 18077522
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.